ClinicalTrials.gg
CompletedNCT02692742MyeloConceptUpdated Nov 24, 2017

Efficacy and Safety Phase IIa Study of Myelo001 in Chemotherapy-Induced Neutropenia

A Phase 2 interventional study of Myelo001 and Placebo in Chemotherapy-Induced Neutropenia, Myelosuppression and Breast Cancer, sponsored by Myelo Therapeutics GmbH. Completed at 23 sites in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-11-24.

Sponsored by Myelo Therapeutics GmbH · Phase 2, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
137
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 678 studies in Breast Neoplasms with a site in Germany — 114 open to participants now, 197 under way, 81 of them phase 3. Breast Neoplasms · Germany.

Enrollment
385th of 580
137 · median 273
Started
2016
with 23 others
Phase 2
165 of 678
14 open now
Registered
366th of 678
by date

Among the 678 studies in Breast Neoplasms with a site in Germany, this one is the 385th largest by enrollment of the 580 interventional ones that give a count, is one of 24 that started in 2016, is one of 165 in phase 2, and was the 366th registered.

Breast Neoplasms

14,840 studies on the registry are indexed under Breast Neoplasms; 3,319 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

114 of the 678 studies in Breast Neoplasms with a site in Germany are open now. Recruiting first, the newest first:

109 more — sign in →

All 114 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 2,398 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 590 (25%) stop at 75 or younger; 103 take children under 18; 213 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 678 studies in Breast Neoplasms with a site in Germany, or all of them as a file.
02

Study summary

Neutropenia is the most serious hematologic toxicity of cancer chemotherapy, often limiting the doses and density of chemotherapy that can be tolerated. The degree and duration of neutropenia determine the risk of infection. Myelo001, a small orally bioavailable molecule, has been shown in chemotherapy- or radiotherapy-induced myelosuppression to stimulate differentiation of peripheral white blood cells (WBC) and bone marrow cells of the leucocytic, lymphocytic, and erythrocytic lineage. The purpose of the MyeloConcept study is to determine the safety and effectiveness of Myelo001 in preventing or reducing chemotherapy-induced neutropenia and myelosuppression in patients receiving chemotherapy due to breast cancer.

Read the detailed description

Phase IIa study, 1:1 randomized, double-blind, placebo-controlled, parallel-design, multi-center study. Each breast cancer patient will be randomly assigned into one of two treatment arms receiving either Myelo001 or placebo as a tablet. Investigational medicinal product is taken as supportive care for 23 consecutive days during chemotherapy treatment. Hematologic and safety parameters as well as actual begin and doses of following chemotherapy cycles will be assessed. A single primary variable will be analyzed with test statistics based on frequent absolute neutrophil measurements. Additionally, in a subgroup of patients biomarkers and pharmacokinetics of Myelo001 will be investigated.

03

Conditions studied

  • Chemotherapy-Induced Neutropenia
  • Myelosuppression
  • Breast Cancer

Browse trials for

Keywords

  • Chemotherapy
  • Chemotherapy-induced Neutropenia
  • Supportive Care
  • Myelosuppression
  • CIN
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patient of any racial origin having fulfilled her 18th birthday on Visit 1 (Screening)
  2. confirmed invasive breast cancer scheduled for or adjuvant chemotherapy (patient with primary wound healing ([R0])
  3. Already selected for neoadjuvant or adjuvant standard of care EC regimen (Epirubicin 90 mg/m2 BSA (body surface area) + Cyclophosphamide 600 mg/m2 BSA q21d (every 21 days)) (with or without treatment with taxanes afterwards)
  4. Risk of chemotherapy-induced Febrile Neutropenia ≤20% according to ASCO Guidelines (2015)
  5. More than 5 days remaining before the planned initiation of the 1st chemotherapy cycle
  6. Performance status Grade 0-1 ()
  7. Echocardiography: No for the scheduled chemotherapy
  8. Haematologic, laboratory and chemistry thresholds at baseline:

    • (ANC) ≥2,000 cells/ mm3 (≥2.0 x 10/L)
    • count ≥100,000/mm3 (≥100 x 10exp9/L)
    • ≥10 g/dL
    • Total \<1.5 x, , ALT \<2.5 x (ULN)
    • Serum creatinine \<2.0 mg/dL
  9. Able to read, understand and willing to sign the form
  10. Able to undergo the investigations and to follow the Visit schedule

Exclusion criteria

Exclusion Criteria:

  1. Suspected allergy to Myelo001 or its
  2. Prior chemotherapy
  3. Prior or concomitant treatment with radiotherapy
  4. Currently on or scheduled for other immunomodulatory or therapies (e.g. TNF inhibitors) during the first chemotherapy cycle
  5. Currently on or scheduled for other immunostimulatory or hematopoietic active therapies (e.g.G-CSF, GM-CSF)
  6. Currently on or scheduled for primary prophylaxis with antibiotics in the first chemotherapy cycle
  7. History of bone marrow transplantation or stem cell transplant
  8. Administration of another medicinal product / medical device within 30 days prior to screening. Participation in non-interventional, national or international cancer registries is allowed.
  9. Already confirmed , or C virus (HBV or ) infection
  10. History of somatic disease/condition that may interfere with the objectives of the study
  11. Any other medical disease or clinical laboratory parameter outside the normal range and of clinical significance according to the investigator
  12. Serious uncontrolled comorbidities
  13. Pregnant or breast-feeding subject
  14. Woman considered to be of who do not use highly effective methods during the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
137 participants (actual)

Study arms

  • Experimental
    Myelo001

    Myelo001 100 mg QD

    Drug: Myelo001

  • Placebo comparator
    Placebo

    Matching Placebo QD

    Drug: Placebo

Interventions

  • Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment

  • DrugPlacebo

    Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment

06

What researchers measure

Primary outcomes

  1. Threshold area over the curve (AOC1) of ANC: Area below the threshold line (ANC 2.0x10^9/L classified as grade 1 neutropenia) and above the individual ANC trajectory

    Time frame: visit 3 to visit 10 (22 days)

  2. Threshold area over the curve (AOC3) of ANC: Area below the threshold line (ANC 1.0x10^9/L classified as grade 3 neutropenia) and above the individual ANC trajectory

    Time frame: visit 3 to visit 10 (22 days)

  3. Duration of ANC < 1.0x10^9/L classified as grade 3 neutropenia

    Time frame: visit 3 to visit 10 (22 days)

Secondary outcomes

  1. Treatment success rate: a) Neutropenia grade ≤2, b) No need for G-CSF rescue therapy, c) No early withdrawal (drop-out).

    Time frame: visit 3 to visit 10 (22 days)

  2. Threshold AOC of ANC (AOC4): Area below the threshold line (ANC 0.5x10^9/L classified as grade 4 neutropenia) and above the individual ANC trajectory

    Time frame: visit 3 to visit 10 (22 days)

  3. Change of Threshold Area over the Curve of lymphocytes

    Time frame: visit 3 to visit 10 (22 days)

  4. Change of Threshold Area over the Curve of leukocytes

    Time frame: visit 3 to visit 10 (22 days)

  5. Change of Threshold Area over the Curve of thrombocytes

    Time frame: visit 3 to visit 10 (22 days)

  6. Proportion of patients with neutropenia grade 1 and higher; 3 and higher, 4, and ANC ≤0.1x 10^9/L

    Time frame: visit 3 to visit 10 (22 days)

  7. Duration of neutropenia grade 1 and higher; 3 and higher, 4, and ANC ≤0.1x 10^9/L

    Time frame: visit 3 to visit 10 (22 days)

  8. ANC at nadir

    Time frame: visit 3 to visit 10 (22 days)

  9. Time to ANC nadir (from start of chemotherapy)

    Time frame: visit 3 to visit 10 (22 days)

  10. Time to ANC recovery from grade 3 neutropenia, i. e. time from onset to time of reaching neutropenia grade ≤2 (ANC ≥ 1.5x10^9/L)

    Time frame: visit 3 to visit 10 (22 days)

  11. Time to ANC recovery from grade 4 neutropenia, i. e. time from onset to time of reaching neutropenia grade ≤2 (ANC ≥ 1.5x10^9/L)

    Time frame: visit 3 to visit 10 (22 days)

  12. Time to ANC recovery from profound neutropenia (ANC ≥ 0.1x10^9/L), i. e. time from onset to time of reaching neutropenia grade ≤2 (ANC ≥1.5x10^9/L)

    Time frame: visit 3 to visit 10 (22 days)

  13. Proportion of patients with rescue therapy

    Time frame: visit 3 to visit 10 (22 days)

  14. Proportion of patients developing febrile neutropenia (body temperature ≥38.3°C by single tympanic or oral measurement) and ANC ≤0.5x 10^9/L (Grade 4)

    Time frame: visit 3 to visit 10 (22 days)

  15. Proportion of patients with CTX dose reduction and/or delay of CTX cycle 2

    Time frame: visit 10 to visit 11

07

Study locations

23 sites
  • Site 20
    Aachen, Germany
  • Site 16
    Aurich, Germany
  • Site 21
    Dresden, Germany
  • Site 26
    Dresden, Germany
  • Site 05
    Erlangen, Germany
  • Site 09
    Esslingen, Germany
  • Site 02
    Frankfurt a.M., Germany
  • Site 13
    Frankfurt a.M., Germany
  • Site 01
    Friedrichshafen, Germany
  • Site 25
    Goslar, Germany
  • Site 11
    Hamburg, Germany
  • Site 10
    Hannover, Germany
  • Site 22
    Hannover, Germany
  • Site 07
    Konstanz, Germany
  • Site 29
    Lübeck, Germany
  • Site 03
    Mainz, Germany
  • Site 23
    Mainz, Germany
  • Site 04
    Offenbach, Germany
  • Site 19
    Oldenburg, Germany
  • Site 17
    Ravensburg, Germany
  • Site 24
    Rosenheim, Germany
  • Site 28
    Tübingen, Germany
  • Site 12
    Westerstede, Germany
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Nov 2017, 20 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 20 months is below that.

Counting every sponsor, half of 1,303 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2016
First posted
Feb 26, 2016
StartActual
Mar 2016
Primary completionActual
Nov 2017
CompletionActual
Nov 2017
Last update
Nov 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02692742
Lead sponsor
Myelo Therapeutics GmbH
Responsible party
Sponsor
First posted
Feb 26, 2016
Start date
Mar 2016
Primary completion
Nov 2017
Completion
Nov 2017
Last update
Nov 24, 2017

Study contacts

Dirk Pleimes, MD
study director · Myelo Therapeutics GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pentanedioic acid imidazolyl ethanamide

Start the discussion